Testosterone Chases Viagra in Libido Race as Doctors Fret
This article is for subscribers only.
Eli Lilly & Co. and Abbott Laboratories are offering help to the 13.8 million American men who have low levels of testosterone. Doctors warn that demand for the treatments could lead to overuse with deadly side effects.
In what may become one of the most sought-after sex enhancement treatments since the introduction of Viagra 14 years ago, new testosterone drugs from Abbott, Lilly and other drugmakers are in hot demand. Prescriptions for testosterone replacement therapies have more than doubled since 2006 to 5.6 million, according to data compiled by Bloomberg. Sales are expected to triple to $5 billion by 2017, according to Global Industry Analysts Inc.